205 related articles for article (PubMed ID: 36211811)
1. Therapeutic Targeting of MYC in Head and Neck Squamous Cell Carcinoma.
Liu S; Qin Z; Mao Y; Zhang W; Wang Y; Jia L; Peng X
Oncoimmunology; 2022; 11(1):2130583. PubMed ID: 36211811
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological inhibition of MYC to mitigate chemoresistance in preclinical models of squamous cell carcinoma.
Liu S; Qin Z; Mao Y; Wang N; Zhang W; Wang Y; Chen Y; Jia L; Peng X
Theranostics; 2024; 14(2):622-639. PubMed ID: 38169606
[No Abstract] [Full Text] [Related]
3. PI3K Inhibitors Curtail MYC-Dependent Mutant p53 Gain-of-Function in Head and Neck Squamous Cell Carcinoma.
Ganci F; Pulito C; Valsoni S; Sacconi A; Turco C; Vahabi M; Manciocco V; Mazza EMC; Meens J; Karamboulas C; Nichols AC; Covello R; Pellini R; Spriano G; Sanguineti G; Muti P; Bicciato S; Ailles L; Strano S; Fontemaggi G; Blandino G
Clin Cancer Res; 2020 Jun; 26(12):2956-2971. PubMed ID: 31969334
[TBL] [Abstract][Full Text] [Related]
4. PLEK2 promotes cancer stemness and tumorigenesis of head and neck squamous cell carcinoma via the c-Myc-mediated positive feedback loop.
Zhao X; Shu D; Sun W; Si S; Ran W; Guo B; Cui L
Cancer Commun (Lond); 2022 Oct; 42(10):987-1007. PubMed ID: 36002342
[TBL] [Abstract][Full Text] [Related]
5. Multi-Omics Identification of Genetic Alterations in Head and Neck Squamous Cell Carcinoma and Therapeutic Efficacy of HNC018 as a Novel Multi-Target Agent for c-MET/STAT3/AKT Signaling Axis.
Khedkar HN; Chen LC; Kuo YC; Wu ATH; Huang HS
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373393
[TBL] [Abstract][Full Text] [Related]
6. EREG-driven oncogenesis of Head and Neck Squamous Cell Carcinoma exhibits higher sensitivity to Erlotinib therapy.
Liu S; Wang Y; Han Y; Xia W; Zhang L; Xu S; Ju H; Zhang X; Ren G; Liu L; Ye W; Zhang Z; Hu J
Theranostics; 2020; 10(23):10589-10605. PubMed ID: 32929368
[No Abstract] [Full Text] [Related]
7. MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma.
Mohan S; Vander Broek R; Shah S; Eytan DF; Pierce ML; Carlson SG; Coupar JF; Zhang J; Cheng H; Chen Z; Van Waes C
Clin Cancer Res; 2015 Sep; 21(17):3946-56. PubMed ID: 25977343
[TBL] [Abstract][Full Text] [Related]
8. Transcription factors: a potential therapeutic target in head and neck squamous cell carcinoma.
Pazhani J; Veeraraghavan VP; Jayaraman S
Epigenomics; 2023 Jan; 15(2):57-60. PubMed ID: 36974620
[TBL] [Abstract][Full Text] [Related]
9. Hypoxia induces TFE3 expression in head and neck squamous cell carcinoma.
Sun ZJ; Yu GT; Huang CF; Bu LL; Liu JF; Ma SR; Zhang WF; Liu B; Zhang L
Oncotarget; 2016 Mar; 7(10):11651-63. PubMed ID: 26872381
[TBL] [Abstract][Full Text] [Related]
10. Pescadillo ribosomal biogenesis factor 1 reduction suppresses tumour growth and renders chemosensitivity of head and neck squamous cell carcinoma.
Li D; Yao C; Ding Z; Liu P; Chen X; Liu W; Yi F; Jiang C; Li H; Liu Y; Wu J
Cancer Med; 2023 Mar; 12(5):5703-5717. PubMed ID: 36217758
[TBL] [Abstract][Full Text] [Related]
11. Immunomodulation via FGFR inhibition augments FGFR1 targeting T-cell based antitumor immunotherapy for head and neck squamous cell carcinoma.
Kono M; Komatsuda H; Yamaki H; Kumai T; Hayashi R; Wakisaka R; Nagato T; Ohkuri T; Kosaka A; Ohara K; Kishibe K; Takahara M; Katada A; Hayashi T; Kobayashi H; Harabuchi Y
Oncoimmunology; 2022; 11(1):2021619. PubMed ID: 35003900
[TBL] [Abstract][Full Text] [Related]
12. Blockade of adenosine A2A receptor enhances CD8
Ma SR; Deng WW; Liu JF; Mao L; Yu GT; Bu LL; Kulkarni AB; Zhang WF; Sun ZJ
Mol Cancer; 2017 Jun; 16(1):99. PubMed ID: 28592285
[TBL] [Abstract][Full Text] [Related]
13. Elevated RET expression enhances EGFR activation and mediates EGFR inhibitor resistance in head and neck squamous cell carcinoma.
Lin C; Lu W; Ren Z; Tang Y; Zhang C; Yang R; Chen Y; Cao W; Wang L; Wang X; Ji T
Cancer Lett; 2016 Jul; 377(1):1-10. PubMed ID: 27090738
[TBL] [Abstract][Full Text] [Related]
14. Mitogen-activated protein kinase inhibition-induced modulation of epidermal growth factor receptor signaling in human head and neck squamous cell carcinoma.
Xie G; Zhu A; Gu X
Head Neck; 2021 Jun; 43(6):1721-1729. PubMed ID: 33533173
[TBL] [Abstract][Full Text] [Related]
15. c-MYC-directed NRF2 drives malignant progression of head and neck cancer via glucose-6-phosphate dehydrogenase and transketolase activation.
Tang YC; Hsiao JR; Jiang SS; Chang JY; Chu PY; Liu KJ; Fang HL; Lin LM; Chen HH; Huang YW; Chen YT; Tsai FY; Lin SF; Chuang YJ; Kuo CC
Theranostics; 2021; 11(11):5232-5247. PubMed ID: 33859744
[No Abstract] [Full Text] [Related]
16. Bioactive phytochemical proanthocyanidins inhibit growth of head and neck squamous cell carcinoma cells by targeting multiple signaling molecules.
Prasad R; Katiyar SK
PLoS One; 2012; 7(9):e46404. PubMed ID: 23050025
[TBL] [Abstract][Full Text] [Related]
17. Blocking of stromal interaction molecule 1 expression influence cell proliferation and promote cell apoptosis in vitro and inhibit tumor growth in vivo in head and neck squamous cell carcinoma.
Li P; Bian XY; Chen Q; Yao XF; Wang XD; Zhang WC; Tao YJ; Jin R; Zhang L
PLoS One; 2017; 12(5):e0177484. PubMed ID: 28494008
[TBL] [Abstract][Full Text] [Related]
18. Bitter melon reduces head and neck squamous cell carcinoma growth by targeting c-Met signaling.
Rajamoorthi A; Shrivastava S; Steele R; Nerurkar P; Gonzalez JG; Crawford S; Varvares M; Ray RB
PLoS One; 2013; 8(10):e78006. PubMed ID: 24147107
[TBL] [Abstract][Full Text] [Related]
19. FGFR1 Is a Potential Prognostic Biomarker and Therapeutic Target in Head and Neck Squamous Cell Carcinoma.
Koole K; Brunen D; van Kempen PM; Noorlag R; de Bree R; Lieftink C; van Es RJ; Bernards R; Willems SM
Clin Cancer Res; 2016 Aug; 22(15):3884-93. PubMed ID: 26936917
[TBL] [Abstract][Full Text] [Related]
20. Notch1 regulates invasion and metastasis of head and neck squamous cell carcinoma by inducing EMT through c-Myc.
Inamura N; Kimura T; Wang L; Yanagi H; Tsuda M; Tanino M; Nishihara H; Fukuda S; Tanaka S
Auris Nasus Larynx; 2017 Aug; 44(4):447-457. PubMed ID: 27595504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
